IDEAYA Biosciences Key Executives
This section highlights IDEAYA Biosciences's key executives, including their titles and compensation details.
Find Contacts at IDEAYA Biosciences
(Showing 0 of )
IDEAYA Biosciences Earnings
This section highlights IDEAYA Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
$16.18
Stock Price
$1.42B
Market Cap
131
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for IDEAYA Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M |
| Cost of Revenue | $- | $4.01M | $2.10M | $1.73M | $39.70M |
| Gross Profit | $7.00M | $19.38M | $48.83M | $26.22M | $-20.16M |
| Gross Profit Ratio | 100.00% | 82.90% | 95.87% | 93.80% | -103.18% |
| Research and Development Expenses | $294.67M | $129.51M | $89.54M | $58.16M | $39.70M |
| General and Administrative Expenses | $39.30M | $28.31M | $23.90M | $20.05M | $15.18M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $39.30M | $28.31M | $23.90M | $20.05M | $15.18M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $333.98M | $157.81M | $113.43M | $78.21M | $54.88M |
| Cost and Expenses | $333.98M | $157.81M | $113.43M | $78.21M | $54.88M |
| Interest Income | $52.50M | $21.47M | $3.85M | $506.00K | $849.00K |
| Interest Expense | $- | $- | $3.85M | $- | $849.00K |
| Depreciation and Amortization | $- | $4.01M | $2.10M | $1.73M | $1.38M |
| EBITDA | $-326.98M | $-130.42M | $-60.40M | $-48.54M | $-33.96M |
| EBITDA Ratio | -4671.07% | -557.71% | -122.72% | -179.91% | -180.90% |
| Operating Income | $-326.98M | $-134.43M | $-62.50M | $-50.27M | $-35.34M |
| Operating Income Ratio | -4671.07% | -574.85% | -122.72% | -179.91% | -180.90% |
| Total Other Income Expenses Net | $52.50M | $21.47M | $3.85M | $506.00K | $849.00K |
| Income Before Tax | $-274.48M | $-112.96M | $-58.66M | $-49.76M | $-34.49M |
| Income Before Tax Ratio | -3921.10% | -483.05% | -115.17% | -178.10% | -176.55% |
| Income Tax Expense | $- | $- | $-3.85M | $-2.23M | $-2.23M |
| Net Income | $-274.48M | $-112.96M | $-54.81M | $-47.53M | $-32.27M |
| Net Income Ratio | -3921.10% | -483.05% | -107.61% | -170.11% | -165.14% |
| EPS | $-3.36 | $-1.96 | $-1.32 | $-1.35 | $-1.31 |
| EPS Diluted | $-3.36 | $-1.96 | $-1.32 | $-1.35 | $-1.31 |
| Weighted Average Shares Outstanding | 81.68M | 57.52M | 41.44M | 35.25M | 24.72M |
| Weighted Average Shares Outstanding Diluted | 81.68M | 57.52M | 41.44M | 35.25M | 24.72M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.00M | $- | $- | $- | $3.92M | $8.04M | $3.54M | $7.88M | $4.02M | $29.70M | $5.85M | $11.36M | $2.96M | $8.98M | $8.76M | $7.25M | $10.57M | $8.97M | $- | $- |
| Cost of Revenue | $- | $- | $1.10M | $1.08M | $1.02M | $986.00K | $998.00K | $960.00K | $558.00K | $925.00K | $1.20M | $464.00K | $425.00K | $15.50M | $14.98M | $11.57M | $12.05M | $10.03M | $8.60M | $9.03M |
| Gross Profit | $7.00M | $- | $-1.10M | $-1.08M | $2.90M | $7.05M | $2.55M | $6.92M | $3.46M | $28.77M | $4.65M | $10.89M | $2.54M | $-6.53M | $-6.22M | $-4.32M | $-1.48M | $-1.06M | $-8.60M | $-9.03M |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 73.90% | 87.70% | 71.80% | 87.80% | 86.10% | 96.90% | 79.40% | 95.90% | 85.70% | -72.70% | -71.10% | -59.60% | -14.00% | -11.80% | 0.00% | 0.00% |
| Research and Development Expenses | $140.18M | $57.15M | $54.53M | $42.80M | $38.77M | $33.70M | $29.18M | $27.86M | $24.71M | $22.37M | $22.80M | $19.66M | $16.11M | $15.50M | $14.98M | $11.57M | $12.05M | $10.02M | $8.60M | $9.03M |
| General and Administrative Expenses | $10.96M | $9.74M | $10.39M | $8.21M | $7.07M | $7.86M | $7.08M | $6.30M | $5.75M | $6.67M | $5.55M | $5.92M | $5.22M | $5.19M | $4.83M | $4.82M | $3.80M | $3.94M | $3.99M | $3.45M |
| Selling and Marketing Expenses | $- | $- | $-1.10M | $- | $-1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.96M | $9.74M | $9.30M | $8.21M | $7.07M | $7.86M | $7.08M | $6.30M | $5.75M | $6.67M | $5.55M | $5.92M | $5.22M | $5.19M | $4.83M | $4.82M | $3.80M | $3.94M | $3.99M | $3.45M |
| Other Expenses | $- | $- | $-54.53M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.42M | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $151.14M | $66.89M | $63.83M | $51.02M | $45.84M | $41.56M | $36.25M | $34.16M | $30.47M | $29.04M | $28.35M | $25.58M | $21.33M | $20.69M | $19.81M | $16.38M | $15.85M | $13.96M | $12.59M | $12.48M |
| Cost and Expenses | $151.14M | $66.89M | $64.93M | $51.02M | $45.84M | $41.56M | $36.25M | $34.16M | $30.47M | $29.04M | $28.35M | $25.58M | $21.33M | $20.69M | $19.81M | $16.38M | $15.85M | $13.96M | $12.59M | $12.48M |
| Interest Income | $13.83M | $15.07M | $12.15M | $11.45M | $7.96M | $6.09M | $4.78M | $2.64M | $2.24M | $955.00K | $443.00K | $207.00K | $157.00K | $131.00K | $104.00K | $114.00K | $145.00K | $70.00K | $199.00K | $435.00K |
| Interest Expense | $- | $- | $- | $- | $25.07M | $- | $- | $- | $2.24M | $955.00K | $443.00K | $207.00K | $- | $349.00K | $104.00K | $114.00K | $849.00K | $70.00K | $199.00K | $435.00K |
| Depreciation and Amortization | $643.00K | $1.01M | $1.10M | $1.08M | $1.02M | $986.00K | $998.00K | $960.00K | $558.00K | $925.00K | $1.20M | $464.00K | $425.00K | $500.00K | $400.00K | $382.00K | $361.00K | $347.00K | $337.00K | $336.00K |
| EBITDA | $-143.50M | $-66.89M | $-64.31M | $-50.40M | $-41.29M | $-32.89M | $-32.09M | $-25.69M | $-25.89M | $1.58M | $-21.64M | $-13.76M | $-17.79M | $-11.26M | $-10.61M | $-8.75M | $-4.92M | $-4.65M | $-12.25M | $-12.14M |
| EBITDA Ratio | -2049.93% | 0.00% | 0.00% | 0.00% | -1042.39% | -417.09% | -922.94% | -333.49% | -657.48% | 5.34% | -363.95% | -102.69% | -619.95% | -125.47% | -121.14% | -120.78% | -49.95% | -55.72% | 0.00% | 0.00% |
| Operating Income | $-144.14M | $-66.89M | $-64.93M | $-51.02M | $-41.91M | $-33.53M | $-32.71M | $-26.28M | $-26.44M | $660.00K | $-22.50M | $-14.22M | $-18.37M | $-11.71M | $-11.05M | $-9.13M | $-5.28M | $-5.00M | $-12.59M | $-12.48M |
| Operating Income Ratio | -2059.11% | 0.00% | 0.00% | 0.00% | -1068.44% | -417.09% | -922.94% | -333.49% | -657.48% | 2.22% | -384.53% | -125.19% | -619.95% | -130.49% | -126.21% | -126.05% | -49.95% | -55.72% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $13.83M | $15.07M | $12.15M | $11.45M | $7.96M | $6.09M | $4.78M | $2.64M | $2.24M | $955.00K | $443.00K | $207.00K | $157.00K | $131.00K | $104.00K | $114.00K | $145.00K | $70.00K | $199.00K | $435.00K |
| Income Before Tax | $-130.31M | $-51.82M | $-52.77M | $-39.57M | $-33.95M | $-27.44M | $-27.93M | $-23.64M | $-24.20M | $1.61M | $-22.06M | $-16.11M | $-18.21M | $-11.58M | $-10.95M | $-9.02M | $-5.13M | $-4.93M | $-12.39M | $-12.04M |
| Income Before Tax Ratio | -1861.60% | 0.00% | 0.00% | 0.00% | -865.54% | -341.38% | -787.98% | -300.00% | -601.72% | 5.44% | -376.96% | -141.78% | -614.65% | -129.03% | -125.02% | -124.48% | -48.58% | -54.93% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $-1.08M | $5.62M | $-1.03M | $-998.00K | $-3.60M | $-2.24M | $-955.00K | $-443.00K | $1.89M | $-20.12M | $-19.97M | $44.00K | $- | $4.77M | $-347.00K | $- | $- |
| Net Income | $-130.31M | $-51.82M | $-52.77M | $-39.57M | $-33.95M | $-27.44M | $-27.93M | $-20.04M | $-21.96M | $2.57M | $-21.61M | $-17.99M | $-18.21M | $-11.58M | $-10.95M | $-9.02M | $-5.13M | $-4.93M | $-12.39M | $-12.04M |
| Net Income Ratio | -1861.60% | 0.00% | 0.00% | 0.00% | -865.54% | -341.38% | -787.98% | -254.33% | -545.97% | 8.65% | -369.39% | -158.38% | -614.65% | -129.03% | -125.02% | -124.48% | -48.58% | -54.93% | 0.00% | 0.00% |
| EPS | $-1.60 | $-0.60 | $-0.68 | $-0.53 | $-0.52 | $-0.46 | $-0.50 | $-0.41 | $-0.46 | $0.06 | $-0.56 | $-0.47 | $-0.47 | $-0.31 | $-0.33 | $-0.28 | $-0.18 | $-0.17 | $-0.59 | $-0.59 |
| EPS Diluted | $-1.60 | $-0.60 | $-0.68 | $-0.53 | $-0.52 | $-0.46 | $-0.50 | $-0.41 | $-0.46 | $0.06 | $-0.56 | $-0.47 | $-0.47 | $-0.31 | $-0.33 | $-0.28 | $-0.18 | $-0.17 | $-0.59 | $-0.59 |
| Weighted Average Shares Outstanding | 81.68M | 86.19M | 77.96M | 75.11M | 65.25M | 60.00M | 56.25M | 48.37M | 48.13M | 40.30M | 38.66M | 38.59M | 38.36M | 37.36M | 32.85M | 31.76M | 29.15M | 28.40M | 21.00M | 20.25M |
| Weighted Average Shares Outstanding Diluted | 81.68M | 86.19M | 77.96M | 75.11M | 65.25M | 60.00M | 56.25M | 48.37M | 48.13M | 41.11M | 38.66M | 38.59M | 38.50M | 37.77M | 32.85M | 31.76M | 29.15M | 28.40M | 21.00M | 20.25M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $84.38M | $157.02M | $68.63M | $92.05M | $72.04M |
| Short Term Investments | $591.94M | $368.10M | $296.20M | $154.72M | $211.55M |
| Cash and Short Term Investments | $676.32M | $525.11M | $373.15M | $368.06M | $283.58M |
| Net Receivables | $3.00K | $18.00K | $211.00K | $1.10M | $1.88M |
| Inventory | $- | $- | $-8.32M | $-121.29M | $- |
| Other Current Assets | $13.39M | $7.50M | $5.41M | $6.25M | $6.29M |
| Total Current Assets | $689.71M | $532.63M | $370.45M | $251.00M | $288.61M |
| Property Plant Equipment Net | $27.74M | $8.41M | $8.99M | $8.66M | $9.48M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $107.49M | $8.32M | $121.29M | $106.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $406.64M | $782.00K | $205.00K | $397.00K | $82.00K |
| Total Non-Current Assets | $434.38M | $116.68M | $17.52M | $130.35M | $9.66M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.12B | $649.32M | $387.97M | $381.35M | $298.27M |
| Account Payables | $15.42M | $6.60M | $4.28M | $2.10M | $953.00K |
| Short Term Debt | $596.00K | $1.75M | $3.74M | $3.40M | $3.08M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $8.57M | $29.04M | $27.61M |
| Other Current Liabilities | $30.05M | $18.76M | $25.01M | $17.27M | $6.99M |
| Total Current Liabilities | $46.07M | $27.10M | $31.72M | $45.16M | $38.64M |
| Long Term Debt | $18.87M | $1.12M | $1.61M | $3.48M | $5.18M |
| Deferred Revenue Non-Current | $- | $- | $5.18M | $31.19M | $56.16M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-5.18M | $-31.19M | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $12.00K |
| Total Non-Current Liabilities | $18.87M | $1.12M | $6.80M | $34.67M | $61.35M |
| Other Liabilities | $- | $- | $349.45M | $301.51M | $198.27M |
| Total Liabilities | $64.94M | $28.23M | $387.97M | $381.35M | $298.27M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $7.00K | $5.00K | $4.00K | $3.00K |
| Retained Earnings | $-622.84M | $-348.36M | $-235.40M | $-176.75M | $-126.99M |
| Accumulated Other Comprehensive Income Loss | $812.00K | $562.00K | $-2.87M | $-712.00K | $7.00K |
| Other Total Stockholders Equity | $1.68B | $968.88M | $587.72M | $478.97M | $325.25M |
| Total Stockholders Equity | $1.06B | $621.09M | $349.45M | $301.51M | $198.27M |
| Total Equity | $1.06B | $621.09M | $349.45M | $301.51M | $198.27M |
| Total Liabilities and Stockholders Equity | $1.12B | $649.32M | $387.97M | $381.35M | $298.27M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.12B | $649.32M | $387.97M | $381.35M | $298.27M |
| Total Investments | $591.94M | $475.59M | $304.51M | $276.02M | $211.55M |
| Total Debt | $19.17M | $2.87M | $3.48M | $5.18M | $6.72M |
| Net Debt | $-65.21M | $-154.15M | $-65.15M | $-86.86M | $-65.31M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $84.38M | $400.28M | $183.05M | $108.34M | $157.02M | $151.85M | $102.84M | $67.24M | $68.63M | $101.95M | $49.11M | $55.29M | $92.05M | $108.43M | $90.43M | $136.75M | $72.04M | $81.24M | $147.54M | $35.46M |
| Short Term Investments | $591.94M | $519.75M | $518.61M | $590.43M | $368.10M | $316.90M | $390.87M | $272.23M | $296.20M | $284.29M | $219.51M | $197.31M | $154.72M | $156.12M | $183.75M | $165.57M | $211.55M | $197.44M | $22.87M | $52.40M |
| Cash and Short Term Investments | $676.32M | $920.03M | $701.66M | $698.77M | $632.61M | $511.14M | $510.09M | $351.21M | $373.15M | $386.24M | $268.62M | $252.60M | $368.06M | $264.55M | $274.18M | $302.32M | $283.58M | $288.84M | $170.41M | $87.86M |
| Net Receivables | $3.00K | $20.00K | $1.00K | $15.00K | $18.00K | $6.70M | $160.00K | $468.00K | $211.00K | $3.45M | $288.00K | $697.00K | $1.10M | $1.02M | $1.32M | $2.92M | $1.88M | $- | $- | $- |
| Inventory | $- | $- | $- | $1 | $532.61M | $-42.39M | $-16.38M | $-4.49M | $-8.32M | $1 | $- | $- | $-121.29M | $- | $1 | $- | $- | $- | $- | $- |
| Other Current Assets | $13.39M | $12.16M | $11.52M | $10.57M | $7.50M | $6.73M | $7.91M | $4.02M | $5.41M | $7.49M | $6.56M | $2.75M | $6.25M | $6.79M | $8.58M | $5.83M | $6.29M | $5.31M | $7.07M | $3.20M |
| Total Current Assets | $689.71M | $932.21M | $713.18M | $709.35M | $532.63M | $482.18M | $501.79M | $351.21M | $370.45M | $393.44M | $272.19M | $256.05M | $251.00M | $268.96M | $279.79M | $308.16M | $288.61M | $288.84M | $173.95M | $89.46M |
| Property Plant Equipment Net | $27.74M | $26.62M | $8.43M | $8.69M | $8.41M | $7.54M | $8.56M | $8.83M | $8.99M | $9.53M | $10.37M | $8.83M | $8.66M | $8.94M | $9.46M | $9.64M | $9.48M | $9.61M | $8.88M | $9.16M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $405.83M | $280.13M | $251.98M | $242.64M | $107.49M | $42.39M | $16.38M | $11.74M | $8.32M | $7.69M | $55.17M | $93.63M | $121.29M | $121.22M | $38.25M | $8.08M | $211.55M | $10.16M | $1.54M | $3.04M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $805.00K | $911.00K | $75.00K | $849.00K | $782.00K | $827.00K | $830.00K | $-7.03M | $205.00K | $252.00K | $280.00K | $362.00K | $397.00K | $323.00K | $897.00K | $217.00K | $-211.36M | $-7.22M | $132.00K | $122.00K |
| Total Non-Current Assets | $434.38M | $307.66M | $260.48M | $252.17M | $116.68M | $50.76M | $25.77M | $13.54M | $17.52M | $17.47M | $65.82M | $102.82M | $130.35M | $130.48M | $48.61M | $17.94M | $9.66M | $12.54M | $10.56M | $12.33M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.12B | $1.24B | $973.66M | $961.53M | $649.32M | $532.94M | $527.56M | $364.75M | $387.97M | $410.91M | $338.01M | $358.87M | $381.35M | $399.44M | $328.40M | $326.10M | $298.27M | $301.38M | $184.51M | $101.79M |
| Account Payables | $15.42M | $12.57M | $15.89M | $6.29M | $6.60M | $5.17M | $5.87M | $4.38M | $4.28M | $3.65M | $4.23M | $3.36M | $2.10M | $2.15M | $2.11M | $1.28M | $953.00K | $1.41M | $952.00K | $684.00K |
| Short Term Debt | $298.00K | $- | $1.21M | $1.15M | $3.49M | $4.19M | $3.92M | $1.92M | $1.87M | $3.65M | $3.57M | $3.48M | $1.70M | $3.32M | $3.24M | $3.16M | $1.54M | $3.00M | $2.41M | $2.35M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $1.44M | $2.82M | $6.25M | $8.57M | $10.27M | $35.85M | $39.22M | $29.04M | $22.93M | $22.13M | $25.51M | $27.61M | $44.85M | $5.22M | $5.43M |
| Other Current Liabilities | $30.35M | $28.09M | $23.64M | $17.52M | $17.01M | $14.09M | $12.73M | $17.27M | $17.00M | $25.63M | $25.42M | $19.14M | $12.32M | $16.68M | $8.29M | $6.18M | $8.53M | $4.92M | $4.06M | $4.31M |
| Total Current Liabilities | $46.07M | $40.66M | $40.74M | $24.96M | $27.10M | $24.89M | $25.34M | $29.82M | $31.72M | $32.73M | $58.09M | $56.96M | $45.16M | $38.64M | $35.77M | $36.13M | $38.64M | $54.17M | $7.43M | $7.35M |
| Long Term Debt | $18.87M | $18.80M | $1.26M | $1.26M | $1.12M | $- | $611.00K | $1.12M | $1.61M | $2.10M | $2.57M | $3.03M | $3.48M | $3.92M | $4.36M | $4.77M | $5.18M | $5.58M | $5.01M | $5.32M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $5.18M | $7.31M | $8.03M | $10.21M | $31.19M | $39.25M | $48.01M | $52.06M | $56.16M | $46.19M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $-3.31M | $-7.31M | $-8.03M | $-10.21M | $-31.19M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.00K | $6.00K | $6.00K | $12.00K | $12.00K | $16.00K | $21.00K |
| Total Non-Current Liabilities | $18.87M | $18.80M | $1.26M | $1.26M | $1.12M | $- | $611.00K | $1.12M | $6.80M | $9.41M | $10.60M | $13.24M | $34.67M | $43.18M | $52.37M | $56.84M | $61.35M | $51.78M | $5.03M | $5.34M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $501.61M | $333.81M | $349.45M | $- | $- | $- | $301.51M | $- | $- | $- | $198.27M | $195.43M | $- | $- |
| Total Liabilities | $64.94M | $59.45M | $42.01M | $26.22M | $28.23M | $24.89M | $527.56M | $364.75M | $387.97M | $42.14M | $68.69M | $70.20M | $381.35M | $81.81M | $88.14M | $92.97M | $298.27M | $301.38M | $12.45M | $12.69M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $126.99M | $- | $- | $- |
| Common Stock | $9.00K | $9.00K | $8.00K | $7.00K | $7.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K |
| Retained Earnings | $-622.84M | $-492.53M | $-440.71M | $-387.94M | $-348.36M | $-314.41M | $-286.97M | $-259.04M | $-235.40M | $-211.20M | $-212.82M | $-190.76M | $-176.75M | $-158.54M | $-146.95M | $-136.01M | $-126.99M | $-121.85M | $-116.92M | $-104.53M |
| Accumulated Other Comprehensive Income Loss | $812.00K | $3.84M | $-1.42M | $-923.00K | $562.00K | $-750.00K | $-1.18M | $-1.41M | $-2.87M | $-4.00M | $-3.63M | $-2.80M | $-712.00K | $-50.00K | $-4.00K | $0 | $7.00K | $35.00K | $57.00K | $0 |
| Other Total Stockholders Equity | $1.68B | $1.67B | $1.37B | $1.32B | $968.88M | $823.20M | $789.75M | $594.25M | $587.72M | $583.97M | $485.76M | $482.23M | $478.97M | $476.21M | $387.21M | $369.13M | $325.25M | $317.24M | $288.92M | $193.63M |
| Total Stockholders Equity | $1.06B | $1.18B | $931.66M | $935.31M | $621.09M | $508.05M | $501.61M | $333.81M | $349.45M | $368.77M | $269.32M | $288.67M | $301.51M | $317.63M | $240.26M | $233.13M | $198.27M | $195.43M | $172.06M | $89.10M |
| Total Equity | $1.06B | $1.18B | $931.66M | $935.31M | $621.09M | $508.05M | $501.61M | $333.81M | $349.45M | $368.77M | $269.32M | $288.67M | $301.51M | $317.63M | $240.26M | $233.13M | $198.27M | $195.43M | $172.06M | $89.10M |
| Total Liabilities and Stockholders Equity | $1.12B | $1.24B | $973.66M | $961.53M | $649.32M | $532.94M | $527.56M | $364.75M | $387.97M | $410.91M | $338.01M | $358.87M | $381.35M | $399.44M | $328.40M | $326.10M | $298.27M | $301.38M | $184.51M | $101.79M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.12B | $1.24B | $973.66M | $961.53M | $649.32M | $532.94M | $527.56M | $364.75M | $387.97M | $410.91M | $338.01M | $358.87M | $381.35M | $399.44M | $328.40M | $326.10M | $298.27M | $301.38M | $184.51M | $101.79M |
| Total Investments | $997.77M | $799.87M | $770.59M | $833.06M | $475.59M | $359.30M | $407.25M | $283.97M | $304.51M | $291.98M | $274.69M | $290.94M | $154.72M | $277.34M | $222.00M | $173.65M | $423.10M | $207.60M | $24.42M | $55.44M |
| Total Debt | $19.17M | $18.80M | $1.87M | $2.41M | $2.87M | $2.10M | $2.57M | $3.03M | $3.48M | $3.92M | $4.36M | $4.77M | $5.18M | $5.58M | $5.97M | $6.35M | $6.72M | $7.09M | $6.22M | $6.50M |
| Net Debt | $-65.21M | $-381.49M | $-181.18M | $-105.94M | $-154.15M | $-149.75M | $-100.27M | $-64.21M | $-65.15M | $-98.03M | $-44.75M | $-50.52M | $-86.86M | $-102.85M | $-84.45M | $-130.40M | $-65.31M | $-74.15M | $-141.33M | $-28.96M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-274.48M | $-112.96M | $-58.66M | $-49.76M | $-34.49M |
| Depreciation and Amortization | $3.83M | $4.01M | $2.10M | $1.73M | $1.38M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $34.75M | $18.49M | $11.63M | $8.24M | $3.61M |
| Change in Working Capital | $11.55M | $-13.21M | $-41.55M | $-17.81M | $84.41M |
| Accounts Receivables | $15.00K | $193.00K | $892.00K | $774.00K | $-1.88M |
| Inventory | $- | $- | $- | $3.79M | $2.29M |
| Accounts Payables | $8.28M | $2.63M | $1.86M | $1.17M | $225.00K |
| Other Working Capital | $3.25M | $-16.04M | $-44.31M | $-23.54M | $83.77M |
| Other Non Cash Items | $-23.23M | $-11.55M | $-695.00K | $1.83M | $562.00K |
| Net Cash Provided by Operating Activities | $-247.58M | $-115.22M | $-87.17M | $-55.78M | $55.46M |
| Investments in Property Plant and Equipment | $-3.86M | $-2.37M | $-3.44M | $-2.64M | $-493.00K |
| Acquisitions Net | $- | $- | $33.40M | $67.02M | $-18.00K |
| Purchases of Investments | $-1.19B | $-595.98M | $-255.81M | $-315.00M | $-242.31M |
| Sales Maturities of Investments | $692.61M | $439.89M | $225.85M | $247.97M | $96.56M |
| Other Investing Activities | $- | $- | $-33.40M | $-67.02M | $18.00K |
| Net Cash Used for Investing Activities | $-502.56M | $-158.46M | $-33.40M | $-69.67M | $-146.24M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $654.23M | $309.76M | $94.96M | $143.25M | $127.23M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $23.32M | $52.95M | $2.20M | $2.20M | $1.52M |
| Net Cash Used Provided by Financing Activities | $677.55M | $362.72M | $97.17M | $145.45M | $128.75M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-72.59M | $89.04M | $-23.41M | $20.01M | $37.97M |
| Cash at End of Period | $85.18M | $157.78M | $68.74M | $92.15M | $72.14M |
| Cash at Beginning of Period | $157.78M | $68.74M | $92.15M | $72.14M | $34.17M |
| Operating Cash Flow | $-247.58M | $-115.22M | $-87.17M | $-55.78M | $55.46M |
| Capital Expenditure | $-3.86M | $-2.37M | $-3.44M | $-2.64M | $-493.00K |
| Free Cash Flow | $-251.44M | $-117.59M | $-90.62M | $-58.42M | $54.97M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-130.31M | $-51.82M | $-52.77M | $-39.57M | $-33.95M | $-27.44M | $-27.93M | $-23.64M | $-24.20M | $1.61M | $-22.06M | $-14.01M | $-18.21M | $-11.58M | $-10.95M | $-9.02M | $-5.13M | $-4.93M | $-12.39M | $-12.04M |
| Depreciation and Amortization | $643.00K | $1.01M | $1.10M | $1.08M | $1.02M | $1.03M | $998.00K | $960.00K | $-492.00K | $925.00K | $1.20M | $464.00K | $448.00K | $451.00K | $444.00K | $382.00K | $361.00K | $347.00K | $337.00K | $336.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-37.83M | $- | $- | $- | $- | $- | $- | $- | $799.00K | $11.49M | $- | $- | $5.13M | $- | $- | $- |
| Stock Based Compensation | $9.48M | $9.21M | $9.73M | $6.31M | $4.80M | $5.30M | $4.73M | $3.66M | $2.98M | $3.00M | $3.04M | $2.60M | $2.06M | $2.20M | $2.06M | $1.92M | $1.05M | $981.00K | $824.00K | $758.00K |
| Change in Working Capital | $3.44M | $-2.28M | $15.70M | $-5.32M | $8.26M | $-5.50M | $-8.71M | $-7.26M | $-525.00K | $-29.62M | $-2.35M | $-9.05M | $-1.43M | $-4.00M | $-4.93M | $-7.46M | $-8.27M | $93.68M | $-2.40M | $1.40M |
| Accounts Receivables | $17.00K | $-19.00K | $14.00K | $3.00K | $6.68M | $-6.54M | $308.00K | $-257.00K | $3.24M | $-3.16M | $409.00K | $406.00K | $-85.00K | $307.00K | $1.60M | $-1.04M | $-1.88M | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $4.05M | $3.13M | $-7.18M | $- | $- | $- | $- | $- | $617.00K | $3.27M | $368.00K | $-470.00K | $1.32M | $- | $- | $- |
| Accounts Payables | $2.98M | $-3.94M | $9.70M | $-453.00K | $1.75M | $-699.00K | $1.60M | $-12.00K | $397.00K | $-449.00K | $1.05M | $863.00K | $-7.00K | $377.00K | $536.00K | $260.00K | $-459.00K | $493.00K | $227.00K | $-36.00K |
| Other Working Capital | $452.00K | $1.68M | $5.99M | $-4.87M | $-4.22M | $-1.38M | $-3.44M | $-7.00M | $-4.16M | $-26.02M | $-3.81M | $-10.32M | $-1.95M | $-7.96M | $-7.43M | $-6.20M | $-7.26M | $93.19M | $-2.63M | $1.44M |
| Other Non Cash Items | $-4.92M | $-5.36M | $-4.42M | $2.61M | $33.95M | $-3.57M | $-2.55M | $-1.56M | $-1.13M | $-86.00K | $169.00K | $349.00K | $-330.00K | $-11.02M | $445.00K | $454.00K | $-4.73M | $129.00K | $25.00K | $5.00K |
| Net Cash Provided by Operating Activities | $-121.66M | $-49.23M | $-32.88M | $-43.81M | $-23.75M | $-30.17M | $-33.46M | $-27.84M | $-23.37M | $-24.17M | $-19.99M | $-19.65M | $-16.66M | $-12.47M | $-12.93M | $-13.72M | $-11.60M | $90.21M | $-13.61M | $-9.54M |
| Investments in Property Plant and Equipment | $-1.10M | $-457.00K | $-973.00K | $-1.32M | $-838.00K | $-603.00K | $-884.00K | $-43.00K | $- | $-1.10M | $-1.94M | $-401.00K | $-605.00K | $-458.00K | $-578.00K | $-1.00M | $-179.00K | $-245.00K | $-69.00K | $33.00K |
| Acquisitions Net | $- | $- | $- | $- | $111.11M | $-51.95M | $120.50M | $-23.56M | $- | $17.58M | $-15.26M | $- | $- | $- | $- | $- | $-18.00K | $- | $- | $-2.00K |
| Purchases of Investments | $-337.04M | $-213.72M | $-164.76M | $-475.78M | $-221.60M | $-81.83M | $-220.25M | $-72.30M | $-65.50M | $-88.08M | $-37.92M | $-64.30M | $-32.57M | $-149.38M | $-94.31M | $-38.74M | $-27.90M | $-188.17M | $-14.99M | $-11.25M |
| Sales Maturities of Investments | $141.03M | $194.15M | $234.29M | $123.14M | $110.50M | $133.78M | $99.75M | $95.86M | $55.23M | $70.50M | $53.18M | $46.94M | $32.76M | $93.53M | $45.51M | $76.18M | $23.53M | $4.83M | $46.05M | $22.16M |
| Other Investing Activities | $- | $- | $69.53M | $-352.65M | $-111.11M | $51.95M | $-120.50M | $23.56M | $-10.28M | $-17.58M | $15.26M | $-17.36M | $192.00K | $-55.85M | $-48.80M | $37.44M | $18.00K | $-183.34M | $31.06M | $-31.00K |
| Net Cash Used for Investing Activities | $-197.11M | $-20.04M | $68.56M | $-353.97M | $-111.94M | $51.35M | $-121.38M | $23.52M | $-10.28M | $-18.68M | $13.32M | $-17.76M | $-413.00K | $-56.31M | $-49.38M | $36.44M | $-4.55M | $-183.58M | $30.99M | $10.91M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-405.00K | $274.66M | $36.32M | $343.65M | $127.42M | $25.98M | $153.81M | $2.56M | $-513.00K | $95.47M | $- | $- | $688.00K | $85.97M | $15.42M | $41.89M | $6.58M | $26.78M | $93.88M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-66.00K | $-9.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.16M | $- | $2.86M | $5.46M | $13.48M | $1.85M | $37.26M | $366.00K | $324.00K | $147.00K | $491.00K | $653.00K | $688.00K | $808.00K | $570.00K | $112.00K | $367.00K | $291.00K | $824.00K | $34.00K |
| Net Cash Used Provided by Financing Activities | $2.75M | $286.50M | $39.18M | $349.11M | $140.89M | $27.83M | $191.06M | $2.93M | $324.00K | $95.70M | $491.00K | $653.00K | $688.00K | $86.78M | $15.99M | $42.00M | $6.95M | $27.07M | $94.70M | $34.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $722.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-316.01M | $218.15M | $74.70M | $-48.67M | $5.92M | $49.01M | $36.22M | $-1.40M | $-33.32M | $52.85M | $-6.18M | $-36.76M | $-16.38M | $18.00M | $-46.33M | $64.72M | $-9.20M | $-66.31M | $112.08M | $1.40M |
| Cash at End of Period | $85.18M | $401.19M | $183.05M | $109.10M | $157.78M | $152.57M | $103.56M | $67.34M | $68.74M | $102.06M | $49.21M | $55.40M | $92.15M | $108.53M | $90.53M | $136.86M | $72.14M | $81.34M | $147.65M | $35.57M |
| Cash at Beginning of Period | $401.19M | $183.05M | $108.34M | $157.78M | $151.85M | $103.56M | $67.34M | $68.74M | $102.06M | $49.21M | $55.40M | $92.15M | $108.53M | $90.53M | $136.86M | $72.14M | $81.34M | $147.65M | $35.57M | $34.17M |
| Operating Cash Flow | $-121.66M | $-49.23M | $-32.88M | $-43.81M | $-23.75M | $-30.17M | $-33.46M | $-27.84M | $-23.37M | $-24.17M | $-19.99M | $-19.65M | $-16.66M | $-12.47M | $-12.93M | $-13.72M | $-11.60M | $90.21M | $-13.61M | $-9.54M |
| Capital Expenditure | $-1.10M | $-457.00K | $-973.00K | $-1.32M | $-838.00K | $-603.00K | $-884.00K | $-43.00K | $- | $-1.10M | $-1.94M | $-401.00K | $-605.00K | $-458.00K | $-578.00K | $-1.00M | $-179.00K | $-245.00K | $-69.00K | $33.00K |
| Free Cash Flow | $-122.76M | $-49.69M | $-33.85M | $-45.14M | $-24.59M | $-30.78M | $-34.34M | $-27.89M | $-23.37M | $-25.27M | $-21.93M | $-20.05M | $-17.26M | $-12.93M | $-13.51M | $-14.73M | $-11.78M | $89.97M | $-13.68M | $-9.51M |
IDEAYA Biosciences Dividends
Explore IDEAYA Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
IDEAYA Biosciences News
Read the latest news about IDEAYA Biosciences, including recent articles, headlines, and updates.
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Designation enables expedited development and priority regulatory review BTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial that we are targeting to present at medical conferences in mid-2025 and H2 2025 Targeting to initiate a Ph3 registrational study in neoadjuvant UM in H1 2025 Neoadjuvant UM has a projected annual incidence of ~12k patients, and is a high unmet medical with no FDA approved systemic therapies SOUTH SAN FRANCISCO, Calif. , March 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , March 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 27, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,600 shares of the Company's common stock to a newly hired employee.
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best-in-class preclinical profile in the MSI-H setting, with a unique binding mode from previously reported WRN inhibitors Phase 1 dose escalation trial ongoing in MSI-H solid tumors with GSK MSI-H prevalence has been reported at approximately 31%, 20%, and 19% in endometrial, colorectal, and gastric cancers, respectively SOUTH SAN FRANCISCO, Calif. , March 26, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for an oral presentation in the New Drugs on the Horizon series, and three poster presentations on IDE275 (GSK959) at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
SOUTH SAN FRANCISCO, Calif. , March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets.
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update(s) in H1 2025, including vision data in plaque brachytherapy patients Targeting median OS readout in ~40 1L MUM patients in 2025 Targeting expansion of study in Q1 2025 of IDE397 in combination with Trodelvy® (sacituzumab govitecan-hziy) in MTAP-deletion UC and clinical data update in 2025; expanded clinical study collaboration into NSCLC Targeting to enable wholly owned IDE397 and IDE892 (IDEAYA PRMT5) clinical combination in H2 2025; IDEAYA and Amgen mutually agree to wind down the IDE397 and AMG 193 clinical combination study Clinical expansion doses selected for DLL3 TOP1i ADC IDE849 by collaboration partner Hengrui, and targeting clinical data update and combo initiation with IDE161 in 2025 Ph1 initiated for Werner Helicase IDE275 (GSK959) and received $7 million milestone from GSK, and targeting medical conference update in H1 2025 Targeting IDE161 expansion with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and combo(s) with TOP1i ADCs in solid tumors in 2025 Targeting 2025 INDs: IDE892 (PRMT5); IDE034 (B7H3/PTK7 ADC); IDE251 (KAT6/7) ~$1.1 billion of cash, cash equivalents and marketable securities as of December 31, 2024, anticipated to fund operations into at least 2028 SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced financial results for the quarter and full year ended December 31, 2024, and provided a business update.
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors MTAP-deletion prevalence in NSCLC is estimated to be approximately 15% SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences, Inc. (Gilead) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion non-small cell lung cancer (NSCLC).
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uveal melanoma; mPFS data expected end of 2025. Darovasertib is also being evaluated in another phase 2 study as a monotherapy targeting neoadjuvant uveal melanoma patients, with data expected in 2025. The global uveal melanoma treatment market is projected to reach $3.22 billion by the end of 2034.
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D.
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
SOUTH SAN FRANCISCO, Calif. , Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
SOUTH SAN FRANCISCO, Calif. , Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P.
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC) DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40% Rational combination opportunities with IDEAYA's DNA Damage Repair (DDR) clinical pipeline, including Phase 1 PARG inhibitor IDE161 Targeting US IND filing for SHR-4849 in H1 2025 SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Dec. 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals Co., Ltd.
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
Independent Data Monitoring Committee (IDMC) recommends move-forward dose in Part 2a of potential registration-enabling trial in 1L HLA-A2-Negative MUM, based on clinical efficacy and safety observed Over 185 patients enrolled in potential registration-enabling trial in 1L HLA-A2-Negative MUM, and the darovasertib and crizotinib combination has received U.S. Food and Drug Administration (FDA) Fast Track designation in MUM SAN FRANCISCO , Dec. 17, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the Independent Data Monitoring Committee (IDMC) recommendation of a move-forward dose and the completion of the Part 2a dose optimization consistent with the U.S. Food and Drug Administration's (FDA) Project Optimus guidelines for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line (1L) setting in patients with HLA-A2-negative (HLA-A2(-)) metastatic uveal melanoma (MUM). "We are pleased with the recommendation of the IDMC and the selection of the move-forward dose for our potential registration-enabling trial evaluating the darovasertib and crizotinib combination in first-line HLA-A2(-) MUM patients.
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Nominated development candidate IDE251, a potential first-in-class KAT6/7 inhibitor IDE251 is targeted to be evaluated in breast and NSCLC with 8p11 amplification, and in the setting of lineage addiction. 8p11 amplification prevalence is projected to be ~15% in breast cancer and ~17.5% in squamous NSCLC Demonstrated robust and durable monotherapy anti-tumor activity in multiple biomarker positive breast and lung xenografts models Targeting IND submission for IDE251 in 2025 SOUTH SAN FRANCISCO, Calif.
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its virtual Investor R&D Day.
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
First patient dosed with combination of IDE161, IDEAYA's investigational, potential first-in-class PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy The IDEAYA-sponsored Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer Selected initial Phase 1/2 expansion dose for IDE161 monotherapy in a priority solid tumor type, based on AE profile and preliminary clinical efficacy observed SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has dosed the first patient in the IDEAYA-sponsored Phase 1 trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS).
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable ADME properties; demonstrating robust MTAP deletion-specific pathway suppression and highly durable antitumor activity in combination with IDE397 IND-enabling studies ongoing and targeting IND-filing for IDE892 in mid-2025 SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced development candidate nomination of IDE892, a potential best-in-class MTA-cooperative PMRT5 inhibitor.
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile.
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo® SOUTH SAN FRANCISCO, Calif. , Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer.
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2024.
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) Option exercised for an exclusive worldwide license for IDE034 from Biocytogen Targeting an IND-filing for IDE034 in 2025 to enable first-in-human clinical evaluation of B7H3/PTK7 topo-I-payload BsADC program IDE034 has the potential to be developed as a monotherapy and in combination with IDEAYA's PARG inhibitor IDE161 B7H3/PTK7 co-expression in lung, colorectal, and head and neck cancer, has been reported at approximately 30%, 46% and 27%, respectively SOUTH SAN FRANCISCO, Calif. and BEIJING , Nov. 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of its option for an exclusive worldwide license from Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
BEIJING & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has n.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for IDYA.